BMS Clinical Trial Access
Sign Now
It is our understanding that there is a gap between the FDAs definition of IM failure and the current guidelines developed by world renowned CML experts*. Our evidence of this is based on the stringent entry criteria imposed on Bristol-Myers Squibb by the FDA for these trials which results in the exclusion of patients, often with fatal consequences.
Allowing treating physicians to use the guidelines developed by CML experts as the entry criteria will permit more patients access to the trials improving data accumulation, while prolonging lives.
Please amend the entry criteria so that patients who have failed IM therapy will have every opportunity to access this promising new drug now.
*(M. Talpaz, B.J. Druker, S.G. OBrien, J. E. Cortes, C. L. Sawyers, A.
Hochhaus, et al)
If you already have an account please sign in, otherwise register an account for free then sign the petition filling the fields below.
Email and password will be your account data, you will be able to sign other petitions after logging in.
Continue with Google